>
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**
Iran Set To Emerge With More Hormuz Leverage Than Before The War Under Draft US-Oman Deal
Health Ranger Report: The Collapse Is Already Here and Americans Are Unaware Of It, Bracken Warns
Ranked: Countries With the Most Government Debt in 2026
Voyager 1 approaches one light day from Earth
Renewable Energy Breakthrough! World's Most Efficient Tesla Turbine System
Meet Sunbird, a nuclear fusion-powered space tug concept from Pulsar Fusion.
China and Russia launch 29-nation AI alliance to rival western control of technology
BREAKING: China has begun manufacturing domestically developed Immersion Deep...
Idaho's High Desert Becomes Hot Spot For Nuclear Power Revolution
The World's Largest Electric Aircraft Is About to Take Its First Flight
Tesla Cybercabs and Superchargers Will Act as Mini Cell Towers for SpaceX Starlink

The study's lead researcher, Dr. Robert Naviaux of the San Diego School of Medicine is an internationally known expert in human genetics, inborn errors of metabolism, metabolomics, and mitochondrial medicine. He is the discoverer of the cause of Alpers syndrome — the oldest Mendelian form of mitochondrial disease — and the developer of the first DNA test to diagnose it. Naviaux is, by far, one of the most qualified people in the world to conduct this study.
During his research, Naviaux noted the transformative results of the drug suramin which was first developed in 1916 and used as an anti-parasitic drug for treating African sleeping sickness and river blindness. After giving a single dose of suramin to boys with autism, between the ages of five and 14, Naviaux recorded something incredible — their symptoms were significantly alleviated.
"After the single dose, it was almost like a roadblock had been released," he said. "If the future studies show that there's continued health benefits, this could be a game-changer for families with autism."